<DOC>
	<DOCNO>NCT02457819</DOCNO>
	<brief_summary>This open label 26 week extension study subject complete SEP360-202 .</brief_summary>
	<brief_title>Dasotraline Pediatric Extension Study</brief_title>
	<detailed_description>This open-label , flexibly-dosed , 26 week extension study child adolescent ADHD complete 6 week double-blind treatment core study ( SEP360 202 ) . This study evaluate long-term safety tolerability dasotraline population .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>At least one subject 's parent/legal guardian must give write informed consent , include privacy authorization , prior study participation . The subject complete inform assent prior study participation . Subject subject 's parent/legal guardian judge investigator willing able comply study procedure visit schedule . Subject complete required assessment Week 6 core study . Subject take medication study drug purpose control ADHD symptom core study . Subject , female , must pregnant breastfeeding . Female subject : must unable become pregnant ( eg , premenarchal , surgically sterile , etc ) ; OR practice true abstinence ( consistent lifestyle ) must agree remain abstinent signing inform consent/assent least 14 day last dose study drug take ; OR sexually active willing use medically effective method birth control signing inform consent/assent least 14 day last dose study drug take . Male subject must willing remain sexually abstinent ( consistent lifestyle ) use effective method birth control , sign informed consent/assent least 14 day last dose study drug take . Any subject whose weight le equal 21 kg OL Baseline visit discuss medical monitor prior enrollment . Subject subject 's parent/legal guardian must able fully comprehend informed consent/assent form ( applicable ) , understand study procedure , able communicate satisfactorily Investigator study coordinator . Subject consider investigator imminent risk suicide , injury self others , damage property . Subject answer `` yes '' `` Suicidal Ideation '' item 4 ( active suicidal ideation intent act , without specific plan ) item 5 ( active suicidal ideation specific plan intent ) lifetime history C SSRS Children 's `` Since Last Visit '' assessment OL Baseline . Subject clinically significant abnormality include physical examination , vital sign , ECG , laboratory test investigator consultation medical monitor considers inappropriate allow participation study . Subject positive urine drug screen ( UDS ) breath alcohol test OL Baseline . Subject parents/legal guardian commitment study would interfere attend study visit . Subject high risk noncompliance investigator 's opinion .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>